Balyasny Asset Management
NVAX icon

Balyasny Asset Management’s Novavax NVAX Stock Holding History

Balyasny Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,700
Closed -$301K – 3414
2025
Q3 		$301K Sell
34,700
-44,300
-56% -$345K ﹤0.01% 2577
2025
Q2 		$498K Buy
79,000
+42,300
+115% +$280K ﹤0.01% 2291
2025
Q1 		$235K Sell
36,700
-21,000
-36% -$174K ﹤0.01% 2534
2024
Q4 		$464K Buy
+57,700
New +$556K ﹤0.01% 2224

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's NVAX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Novavax (NVAX) in Q1 2026, closing a stake of 384,991 shares — an estimated $2.59M sold.

Balyasny Asset Management first reported a position in NVAX in Q3 2015 and held it in 14 quarters. The position peaked at $18M in Q2 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Balyasny Asset Management reported no remaining Novavax position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 384,991 Novavax shares in Q1 2026, an estimated $2.59M.
  • Balyasny Asset Management first reported a position in Novavax in Q3 2015 and held it in 14 quarters.
  • Balyasny Asset Management's Novavax position peaked at $18M in Q2 2021.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.